Skip to content

Development and Application of an Artificial Intelligence Prediction Model for Postoperative Tumor Recurrence in Gallbladder Cancer Patients Undergoing Surgical Resection Based on Multimodal Big Data

Development and Application of an Artificial Intelligence Prediction Model for Postoperative Tumor Recurrence in Gallbladder Cancer Patients Undergoing Surgical Resection Based on Multimodal Big Data

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600119134
Enrollment
Unknown
Registered
2026-02-24
Start date
2026-02-25
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gallbladder Cancer

Interventions

Sponsors

The First Affiliated Hospital of Army Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Confirmed gallbladder cancer by postoperative pathological examination; 2.Underwent radical resection for gallbladder cancer (R0 or R1 resection), with a surgical extent including at minimum cholecystectomy plus hepatic wedge resection/segment IVb + V resection/right hemihepatectomy combined with regional lymphadenectomy; 3.Complete preoperative baseline clinical data were available, including age, gender, comorbidities, laboratory examinations, and other indicators; 4.Preoperative contrast-enhanced abdominal CT or MRI imaging data of acceptable quality were available (for radiomic analysis); 5.Complete postoperative paraffin-embedded pathological specimens and sections were available (for pathomic analysis and genomic detection); 6.Detailed perioperative data were available for the evaluation of "textbook outcome"; 7.Standardized postoperative follow-up data were available, including definitive records of overall survival and recurrence-free survival.

Exclusion criteria

Exclusion criteria: 1.Patients with synchronous malignant tumors in other organs; 2.Patients with distant metastasis (M1) detected on preoperative imaging or intraoperatively; 3.Patients who received neoadjuvant chemotherapy, radiotherapy or immunotherapy preoperatively (to ensure that preoperative multimodal data can truly reflect the initial status of the tumor); 4.Patients with missing or poor-quality key multimodal data (e.g., imaging, pathological specimens) that render further analysis unfeasible; 5.Patients lost to follow-up or with a follow-up duration of less than 12 months (unless death or tumor recurrence occurred within the 12-month period).

Design outcomes

Primary

MeasureTime frame
Recurrence-free survival;Overall survival;

Countries

China

Contacts

Public ContactZhipeng Liu

The First Affiliated Hospital of Army Medical University

liuzhipeng1115@163.com+86 23 6875 4035

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 14, 2026